ReviewWorld journal of transplantation2016
Survival of encapsulated islets: More than a membrane story.
Review in World journal of transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 126 citations in OpenAlex.
- Pancreatic tissue engineering: towards a vascularized bioengineered cure for diabetes.Frontiers in transplantation · 2026Review
- Low Responsiveness of Macroencapsulated Human Islets Towards Glucose Challenge Despite Excellent Survival in Silicone-Based Oxygen-Delivering Devices.Bioengineering (Basel, Switzerland) · 2025Article
- Inflammation-induced subcutaneous neovascularization for the long-term survival of encapsulated islets without immunosuppression.Nature biomedical engineering · 2024Article
- 3D bioprinted mesenchymal stem cell laden scaffold enhances subcutaneous vascularization for delivery of cell therapy.Biomedical microdevices · 2024Article
- Advances and challenges of the cell-based therapies among diabetic patients.Journal of translational medicine · 2024Review
- A bioengineered artificial interstitium supports long-term islet xenograft survival in nonhuman primates without immunosuppression.Science advances · 2024Article
- Replenishable prevascularized cell encapsulation devices increase graft survival and function in the subcutaneous space.Bioengineering & translational medicine · 2023Article
- Promoting β-cells function by the recapitulation of in vivo microenvironmental differentiation signals.Cell and tissue research · 2023Article
- Type 1 diabetes and engineering enhanced islet transplantation.Advanced drug delivery reviews · 2022Review
- Integrating Additive Manufacturing Techniques to Improve Cell-Based Implants for the Treatment of Type 1 Diabetes.Advanced healthcare materials · 2022Review
- Article
- Optimization of an OScientific reports · 2022Article
- Engineering Islets From Stem Cells: The Optimal Solution for the Treatment of Diabetes?Frontiers in immunology · 2022Review
- Superporous agarose scaffolds for encapsulation of adult human islets and human stem-cell-derived β cells for intravascular bioartificial pancreas applications.Journal of biomedical materials research. Part A · 2021Article
- Developing a morphomics framework to optimize implant site-specific design parameters for islet macroencapsulation devices.Journal of the Royal Society, Interface · 2021Article
- A bioinspired scaffold for rapid oxygenation of cell encapsulation systems.Nature communications · 2021Article
- Calculation of Mass Transfer and Cell-Specific Consumption Rates to Improve Cell Viability in Bioink Tissue Constructs.Materials (Basel, Switzerland) · 2021Article
- Design Considerations for Macroencapsulation Devices for Stem Cell Derived Islets for the Treatment of Type 1 Diabetes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- A Low-Cost Open Source Device for Cell Microencapsulation.Materials (Basel, Switzerland) · 2020Article
- In vitro platform establishes antigen-specific CD8Biomaterials · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At present, proven clinical treatments but no cures are available for diabetes, a global epidemic with a huge economic burden. Transplantation of islets of Langerhans by their infusion into vascularized organs is an experimental clinical protocol, the first approach to attain cure. However, it is associated with lifelong use of immunosuppressants. To overcome the need for immunosuppression, islets are encapsulated and separated from the host immune system by a permselective membrane. The lead material for this application is alginate which was tested in many animal models and a few clinical trials. This review discusses all aspects related to the function of transplanted encapsulated islets such as the basic requirements from a permselective membrane (e.g., allowable hydrodynamic radii, implications of the thickness of the membrane and relative electrical charge). Another aspect involves adequate oxygen supply, which is essential for survival/performance of transplanted islets, especially when using large retrievable macro-capsules implanted in poorly oxygenated sites like the subcutis. Notably, islets can survive under low oxygen tension and are physiologically active at > 40 Torr. Surprisingly, when densely crowded, islets are fully functional under hyperoxic pressure of up to 500 Torr (> 300% of atmospheric oxygen tension). The review also addresses an additional category of requirements for optimal performance of transplanted islets, named auxiliary technologies. These include control of inflammation, apoptosis, angiogenesis, and the intra-capsular environment. The review highlights that curing diabetes with a functional bio-artificial pancreas requires optimizing all of these aspects, and that significant advances have already been made in many of them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.